Peapod Bio provides high‑throughput assay solutions for small‑molecule and peptide drug discovery, enabling rapid go/no‑go decisions. Their platform combines label‑free technologies with state‑of‑the‑art MALDI mass spectrometry and orthogonal approaches to deliver fast, high‑quality assay development and screening results. By partnering as a CRO, Peapod Bio helps programs accelerate progress toward clinical candidates.
Funding
Funding not disclosed
Founders
Product
Problem
Drug discovery teams often face slow assay development cycles and rely on labeled techniques that can introduce bias, limiting the speed and reliability of small‑molecule and peptide screening programs.
Solution
Peapod Bio offers high‑throughput, label‑free and beyond‑label‑free assay platforms that integrate state‑of‑the‑art MALDI mass spectrometry with orthogonal detection methods. These solutions enable rapid assay development and large‑scale screening without the need for fluorescent or radioactive labels, delivering high‑quality data that support fast go/no‑go decisions. By providing a CRO‑style service, Peabod Bio accelerates the transition from hit identification to lead optimization while maintaining data integrity and reproducibility.
Target Audience
Primary customers are pharmaceutical and biotech R&D teams focused on small‑molecule and peptide drug discovery that require rapid, reliable high‑throughput screening solutions.
Features
- High‑throughput MALDI‑MS workflow capable of processing thousands of samples per day
- Label‑free detection eliminates assay interference and reduces development time
- Beyond‑label‑free orthogonal assays for peptide and complex small‑molecule targets
- Integrated data analysis pipeline delivering quantitative, reproducible results
- Flexible service model that supports custom assay design and full‑scale screening campaigns